GlassScriptPhysician profile
David P Van Dam
NPI 1992877278
$9,877.46
in general payments reported to CMS, 2019-2025
30 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $261 · 2021: $1,253 · 2022: $1,888 · 2023: $1,853 · 2024: $1,672 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,903.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,944.78 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Merz North America, INC. | $1,501.46 | 2019-2022 | |
| Genzyme Corporation | $860.02 | 2019-2025 | |
| Janssen Biotech, INC. | $776.98 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $758.12 | 2019-2025 | |
| Lilly USA, LLC | $628.15 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $605.39 | 2019-2025 | Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $596.33 | 2019-2025 | Aklief, Oracea, Twyneo |
| Regeneron Healthcare Solutions, INC. | $376.52 | 2021-2025 | Dupixent |
| Allergan, INC. | $368.01 | 2019-2022 | |
| Amgen INC. | $243.97 | 2022-2024 | Otezla |
| Dermavant Sciences, INC. | $204.48 | 2022-2023 | Vtama |
| Pfizer INC. | $161.08 | 2022-2024 | |
| Incyte Corporation | $127.78 | 2023-2025 | Opzelura |
| Almirall LLC | $109.07 | 2021-2023 | Klisyri, Seysara |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $91.75 | 2022-2024 | |
| Ucb, INC. | $85.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.60 | 2023-2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $71.47 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.98 | 2024-2025 | Cabtreo |
| Verrica Pharmaceuticals INC. | $30.59 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $28.54 | 2023 | Keytruda |
| Biofrontera INC. | $26.61 | 2025 | |
| Vyne Pharmaceuticals INC. | $24.90 | 2021 | |
| Celgene Corporation | $24.33 | 2019 | |
| Glaxosmithkline, LLC. | $23.08 | 2025 | Bexsero, Penmenvy |
| Arcutis Biotherapeutics, INC. | $21.65 | 2023 | |
| Botanix Sb INC | $20.93 | 2025 | Sofdra |
| Sandoz INC. | $20.80 | 2020 | |
| Journey Medical Corporation | $13.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Van Dam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.